The INSIGHT international, multicenter, randomized, placebo-controlled pivotal Phase II/III clinical study will be conducted with a 3.7 g/day dose of TOTUM•854 on 400 volunteers; The INSIGHT
TOTUM•63, prediabetes Obtaining of the patent in China; Scientific publications validating the R&D work performed; Announcement of the implementation of a clinical mode of action
The scientific papers, presenting preclinical and clinical Phase I/II results for TOTUM•63, have been accepted and published in three international peer-reviewed journals: the American Journal of
Shareholders are invited to vote remotely Regulatory News: Valbiotis (Paris:ALVAL) (FR0013254851 ALVAL, PEA SME eligible), a Research and Development company committed to scientific innovation
VALBIOTIS Releases Its 2020 Annual Results
2020 highlights and results
Global strategic partnership with Nestlé Health Science for the development and marketing of TOTUM-63, a plant-based active substance with clinically proven metabolic health benefits in prediabetic subjects.
Launch of REVERSE-IT, a global pivotal Phase II/III clinical trial of TOTUM-63 for reducing Type 2 Diabetes risk factors.
New milestones achieved with TOTUM-070, a plant-based active substance for lowering LDL-cholesterol, a risk factor for cardiovascular disease.
€14.6m in cash as at December 31, 2020.
Post-balance sheet events and outlook
Important milestones are expected to be reached in the development of TOTUM-070 (reduction in blood LDL-cholesterol levels).